Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats  by Schwasinger-Schmidt, Tiffany et al.
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The  ultimate  treatment  goal  of  diabetes  is  to  preserve  and  restore  islet  cell  function.  Treatment  of certain
diabetic  animal  models  with  incretins  has  been  reported  to  preserve  and  possibly  enhance  islet  function
and  promote  islet  cell  growth.  The  studies  reported  here  detail  islet  cell  anatomy  in animals  chronically
treated  with  the  incretin  analog,  liraglutide.  Our  aim  was  to quantitatively  and  qualitatively  analyze  islet
cells  from  diabetic  animals  treated with  vehicle  (control)  or liraglutide  to  determine  whether  normal  islet
cell anatomy  is  maintained  or enhanced  with  pharmaceutical  treatment.  We  harvested  pancreata  from
liraglutide  and  vehicle-treated  Zucker  Diabetic  Fatty  (ZDF)  rats  to examine  islet  structure  and  function
and  obtain  isolated  islets.  Twelve-week-old  male  rats  were  assigned  to 3  groups:  (1)  liraglutide-treated
diabetic,  (2)  vehicle-treated  diabetic,  and  (3)  lean  non-diabetic.  Liraglutide  was  given SC  twice  daily
for  9  weeks.  As  expected,  liraglutide  treatment  reduced  body  weight  by  15%  compared  to  the vehicle-
treated  animals,  eventually  to levels  that were  not  different  from  lean  controls.  At the  termination  of
the  study,  blood  glucose  was signiﬁcantly  less  in the  liraglutide-treated  rats compared  to  vehicle  treated
controls  (485.8  ± 22.5  and  547.2  ±  33.1 mg/dl,  respectively).  Insulin  content/islet  (measured  by  immuno-
histochemistry)  was  34.2 ± 0.7  pixel  units  in  vehicle-treated  rats,  and  54.9  ±  0.6  in  the  liraglutide-treated
animals. Glucose-stimulated  insulin  secretion  from  isolated  islets  (measured  as the stimulation  index)
was  maintained  in  the liraglutide-treated  rats,  but  not in  the vehicle-treated.  However,  liraglutide  did  not
preserve  normal  islet  architecture.  There  was  a decrease  in  the glucagon-positive  area/islet  and  in the  -
cell  numbers/area  with  liraglutide  treatment  (6.5  cells/ﬁeld),  compared  to  vehicle  (17.9 cells/ﬁeld).  There
was an increase  in  -cell  numbers,  the  - to  -cell  ratio  that  was  statistically  higher  in  the  liraglutide-
treated  rats  (24.3  ±  4.4)  compared  to vehicle  (9.1  ±  2.8).  Disrupted  mitochondria  were  more  commonly
observed  in  the  -cells  (51.9  ± 10.3%  of  cells)  than  in the  -cells  (27.2  ±  4.4%)  in the liraglutide-treated
group.  While  liraglutide  enhanced  or maintained  growth  and function  of certain  islet cells,  the overall
ratio  of  - to -cells  was decreased  and  there  was  an  absolute  reduction  in  islet  -cell content.  There
was  selective  disruption  of intracellular  -cell  organelles,  representing  an  uncoupling  of the  bihormonal
islet  signaling  that  is  required  for normal  metabolic  regulation.  The  relevance  of the ﬁndings  to  long-term
liraglutide  treatment  in  people  with  diabetes  is  unknown  and  should  be investigated  in appropriately
designed  clinical  studies.
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1. Introduction
The incretin hormones are peptides released by the gastroin-
testinal tract in response to the ingestion of food. These hormones
enhance insulin secretion and regulate glucose homeostasis by
inhibiting glucagon secretion, slowing gastric emptying, and con-
trolling satiation, ultimately controlling body weight [1]. GLP-1
is one of the major incretin hormones that rapidly stimulates
insulin release. Several peptide drugs have been designed to mimic
Open access under CC BY-NC-ND license.the action of GLP-1, among them exenatide and liraglutide, with
the long-term goal of improving blood glucose regulation and
enhancing weight loss. In 2010, the Food and Drug Administration
icense.
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pproved liraglutide for daily, chronic treatment of adults with
ype 2 diabetes [2]. Liraglutide has 97% homology in amino acid
equence with endogenous GLP-1 and is resistant to enzyme inac-
ivation [3]. Administration of liraglutide to people with type 2
iabetes signiﬁcantly reduced fasting glucose levels, decreased
bA1c values, and decreased body weight [4]. There is indirect
vidence, based on the long-term stability of HbA1c levels, that
reatment with GLP-1 stabilizes islet cell function in humans, and
ay  slow the usual progression of insulin depletion over time in
ype 2 diabetes [5].
Diabetic ZDF rats, and those with 60% pancreatectomies,
reated with liraglutide have increased -cell mass, which is more
rominent in the most obese animals as compared to the glucose-
ontrolled animals [6]. -Cell glucose sensitivity was  restored with
LP-1 treatment, resulting in increased insulin secretion in rats.
onversely glucagon secretion was inhibited [7,8]. The glucagon
nhibition is thought to be due to the immediate effect of the
ncretin, as direct exposure of an -cell culture line to GLP-1
lso inhibited glucagon release [9]. In conditions where glucagon
roduction and secretion are excessive, such inhibition may  be
eneﬁcial [10]. While improved -cell regulation may  be a goal,
bnormal loss of -cells and/or their function would not be optimal
or glucose homeostasis.
The increase in islet cell mass with improvement in glycemic
ontrol raises the possibility that treatment with GLP-1 analogs
natomically and, to some extent, physiologically reverses the
nsulin deﬁciency characteristic of type 2 diabetes. The purpose
f this study was to determine whether the islets remaining after
ong-term GLP-1 administration possessed normal morphology
nd function using an animal model of type 2 diabetes with empha-
is on -cells. Arguably, any treatment that enhances islet cell
unction in diabetes should preserve or enhance normal islet cell
tructure and function.
. Methods
.1. Animal model
Male ZDF rats of 12 weeks of age on arrival were assigned
o 3 groups: (1) liraglutide-treated diabetic (strain code #370,
bese fa/fa), (2) vehicle-treated diabetic (strain code #370, obese
a/fa), (3) lean non-diabetic (strain code #380, lean fa/+). Rats
ere purchased from Charles River Laboratory (Saint Louis, MO)
nd allowed one week for acclimation prior to experimentation.
he rats received husbandry services at the Laboratory Animal
esources facility at the University of Kansas Medical Center. The
ats were allowed food (Purina 5008) and water ad libitum and were
aintained on a 12:12 light–dark cycle. All animal procedures were
erformed according to the IACUC guidelines of the University of
ansas Medical Center and the studies were approved by the local
nimal use committee.
Body weights were recorded weekly on all rats. Blood glucose
evels were assessed by a digital blood glucose meter (Accu-Chek
ctive, Roche Diagnostics, Indianapolis, IN). Weekly blood glucose
evels were calculated as an average of daily levels measured for a
iven week. Hemoglobin A1c (HbA1c) levels were determined by
 home evaluation unit (A1C Now At Home System, Bayers, Pitts-
urgh, PA). When rats had blood glucose or HbA1c levels higher
han the range of detection by the instrument, statistical analy-
is of the data followed previously published procedures [11,12].
rieﬂy, the highest detectable value for blood glucose (600 mg/dl)
as substituted for the missing data.
Animals were administered subcutaneous liraglutide for 9
eeks bid (6 mg/ml; dissolved in vehicle of disodium hydrogen
hosphate dihydrate, polyethylene glycol and H2O) at a ﬁnal doseological Research 76 (2013) 58– 66 59
of 0.225 g/g body weight. At the termination of the study, rats
were over-anesthetized with tribromoethanol and the pancreas or
isolated islets processed according to the methods listed below.
2.2. Islet isolation
At the termination of the study the pancreata were cannu-
lated in situ via the common bile duct, and distended with cold
collagenase (CLS-1, Worthington Biochemical in Leibovitz L15 at
450 U/ml). The distended pancreas was  excised and incubated for
20–30 min  with gentle tumbling in a 37 ◦C incubator. The contents
of the tube were placed in diluted ice-cold Hank’s Balanced Salt
Solution (HBSS) containing 5% fetal calf serum. The digest was
allowed to settle at 1 × g and the supernatant removed and the
process repeated. The washed digest was  passed through a 500 m
screen and sedimented for 1 min  at 300 × g. The pellet was  mixed
with 10 ml  of 1.110 g/ml Histopaque (density = 1.1085, Sigma Diag-
nostics Inc.) and centrifuged. The islets ﬂoating on the interphase of
the gradient were collected, sedimented, and cleaned using a sterile
40 m mesh cell strainer and HBSS with 5% fetal calf serum. Islets
were placed into CMRL 1066 containing 2 mM glutamine, 10% fetal
bovine serum and 1% antibiotic/antimycotic solution.
2.3. Insulin secretion
Islets were placed in duplicate wells and assigned to three
groups: basal glucose (1 mM),  low glucose (3 mM),  and high glu-
cose (20 mM).  All wells were preincubated for 30 min in RPMI
1640 containing 3 mM glucose in a 37 ◦C containing 5% CO2. After
preincubation, media were removed from each well and discarded.
Basal, low or high glucose solutions were added to the dupli-
cates. After 30 min  static incubation in the 37 ◦C and 5% CO2, the
islets were sedimented and the conditioned medium was  col-
lected to determine insulin content and frozen at −80 ◦C. Insulin
concentration was  determined by ELISA (ALPCO, Windham, NH).
The stimulation index was calculated as the amount of insulin
released at low or high glucose divided by the basal insulin
amount.
2.4. Electron microscopy
Electron microscopy was  conducted using 2 mm sections of pan-
creatic tissue ﬁxed in 2% glutaraldehyde. Samples were rinsed twice
in 0.1 M sodium cacodylate buffer for 10 min prior to post ﬁxation
in 1% osmium tetroxide for 1 h. Rinsing with distilled water was fol-
lowed by a gradual ethanol dehydration (30%, 70%, 80%, 95%, 100%)
for 10 min  each. Samples were rinsed twice in propylene oxide for
15 min  prior to being inﬁltrated in a mixture of propylene oxide
and Embed 812 resin (Electron Microscopy Sciences, Ft. Washing-
ton, PA) overnight. BEEM capsules were used to embed the samples
in fresh resin prior to curing overnight in a 70 ◦C oven. Thin sections,
80 nm in diameter, were cut using a Leica UCT ultramicrotome and
placed on 300 mesh thin bar grids. Contrast was applied to the sec-
tions by adding uranyl acetate followed by Sato’s lead stain. Images
of ZDF pancreatic islets were captured from random tissue sections
using a J.E.O.L JEM 1400 transmission electron microscope.
Analysis of the EM images was completed by a blinded inves-
tigator who  had not participated in the animal portion of the
study. Analysis included calculating the number of insulin granules,
and evaluating the mitochondria quality. Images were analyzed
in Adobe Photoshop (Adobe Systems, Inc.) or Scion Image (Scion
Corp.). Insulin granules were counted manually within an assigned
area on each micrograph using previously published procedures
[13,14]. The insulin granules were easily identiﬁed by their halo
presentation, making them unique from the other secretory gran-
ules such as those containing glucagon or somatostatin. The level
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f intact mitochondria was determined using the published Mito-
hondrial Quality Index [15]. Brieﬂy, individual mitochondria were
ssigned one of the following grades: 1 – fully intact, 2 – dis-
uption of the cristae (typically from swelling or loss of integrity
f the inner membrane), 3 – disruption of the outer mitochon-
rial membrane, and 4 – disruption of the cristae and the outer
embrane.
.5. Immunohistochemistry and immunohistoﬂuorescence
The pancreata were rapidly harvested and ﬁxed in 10% nor-
al  buffered formalin using our published protocols [16]. Sections
ere blocked in 10% normal donkey serum (NDS), 1.0% bovine
erum albumin (BSA), and 0.03% Triton X-100 diluted in 0.1 M
BS, pH 7.4 for 30 min. Both primary and secondary antibod-
es were diluted in 1% NDS, 1% BSA, and 0.03% Triton X-100.
lides were mounted with anti-fading agents Gel/Mount (Biomeda,
oster City, CA, PA, #M01). The primary antibodies consisted
f: anti-insulin (1:100, Abcam, Cambridge, MA,  #ab7842), anti-
lucagon (1:300, Abcam, #ab10988), anti-somatostatin (1:300,
bcam, #ab53165) and anti-Ki67 [SP6] proliferation marker (1:100,
bcam, #ab16667), anti-proinsulin (1:200, Abcam, #ab50805)
nd CD34 (1:200, Abcam, #ab812894). Corresponding secondary
ntibodies were conjugated with Dylight 488 (1:400, Jackson
mmunoResearch Laboratories Inc., West Grove, PA, #706-485-
48), Alexa 555 (1:400, Molecular Probes, Eugene, OR, #A31570),
nd Alexa 647 (1:400, Molecular Probes, #A31573). Images were
ollected using a Nikon C1Si confocal microscope.
Insulin immunohistochemistry (IHC) was completed on paraf-
n embedded pancreatic tissue using anti-insulin (1:100, Santa
ruz Biotechnology, Inc., Santa Cruz, CA, #sc-9168) and Histostain
lus Rabbit Primary (Invitrogen, Frederick, MD,  #85-6143) in com-
ination with AEC (3-amino-9-ethyl-carbazole) chromogen as a
ubstrate of Horseradish Peroxidase (HRP) enzyme. Slides for IHC
ere prepared in the same manner as for IF. After the permeabil-
zation step, a blocking solution was applied. The IHC procedure
as conducted according to the manufacturer instructions.
After staining, the slides were placed on coverslips in mount-
ng medium Clear-Mount with Tris Buffer (Electron Microscopy
ciences, Hatﬁeld, PA, #17985-12). The speciﬁcity of insulin
mmunoreactivity was conﬁrmed by omitting the primary antibod-
es from some of the collected sections. The staining was observed
y light microscopy (Nikon Eclipse 80i). Images were analyzed with
s Adobe Photoshop CZ4 extended software, by determining the
verage pixel value of staining per cell or per islet. Background
taining was subtracted from each value.
Islet density was deﬁned as the number of islets per ﬁeld using a
0× objective. Islet size was estimated by measuring the diameter
f the islet under the software Nikon EZ-C1 3.0 FreeViewer. For the
ell composition analysis, the relative proportion of -, - or -cells
n one islet was evaluated by counting the number of individual
ypes of cell and dividing by the total sum of endocrine (,  and )
ells per islet. Gross islet morphology was categorized as either
1) intact, (2) disrupted or (3) scattered cells. Intact islets were
eﬁned as having a distinct border with a circular or ellipsoidal
hape. Disrupted islets also contained an identiﬁable border, but
ere missing sections of cells stained for either insulin, glucagon,
r somatostatin. For an islet to be classiﬁed as disrupted, at least 25%
f the area had to lack staining for insulin, glucagon or somatostatin.
cattered cells were deﬁned as fewer than 10 insulin, glucagon, or
omatostatin positive cells in an area. Multiple sequential sections
ere analyzed to make sure that a scattered appearance was  nothe tip of an islet, but truly a small number of endocrine cells alone.
ll islet morphology, density, and pixel values were analyzed by a
linded investigator who did not participate in the in vivo portion
f the study or in the collection of the images.ological Research 76 (2013) 58– 66
2.6. Statistics
A t-test was  used to compare total insulin content. Body weight
and blood glucose data were analyzed using repeated measures
ANOVA. Insulin secretion was analyzed using one-way ANOVA. For
the immunostaining experiments, nested ANOVA was  utilized. All
ﬁgures include means ± SE. p-Value, deﬁned as <0.05, was  consid-
ered statistically signiﬁcant.
3. Results
3.1. Metabolic effects
Over the 9 week course of the study, the body weight of the
diabetic ZDF rats increased over the matched lean animals (Fig. 1A,
p < 0.03). Administration of liraglutide was associated with a body
weight that was  not statistically different from the lean animals,
and was  less than the vehicle-treated diabetic rats. Blood glu-
cose levels increased in both diabetic groups compared to the lean
non-diabetic controls at each time point tested (Fig. 1B; p < 0.001).
Liraglutide signiﬁcantly reduced the blood glucose levels in the
treated ZDF rats as compared to the vehicle-treated animals.
At the termination of the study, glucose tolerance tests were
administered to the liraglutide and vehicle-treated animals. There
was no difference in the fasting glucose measurements prior to the
initiation of the experiment (Fig. 1C). However, the blood glucose of
the vehicle-treated animals rose to levels above the detection limits
of the procedure after the glucose injection (at 30 and 60 min). Dur-
ing the same time points, the liraglutide-treated animals had mean
blood glucose values of 529 ± 50 and 542 ± 51 mg/dl, respectively.
There was  no difference between groups in the glucose values 2 h
after the injection of glucose.
3.2. Insulin content
Immunohistochemistry was  used to identify islets from the pan-
creas of each group of rats. Obviously, it was difﬁcult to ﬁnd intact
islets from the 2 diabetic groups. The results demonstrated dif-
ferences in the insulin staining intensity between the 3 groups.
As expected, the non-diabetic lean controls had the most intense
insulin staining (Fig. 2A), followed by the liraglutide-treated ani-
mals (Fig. 2C). Pancreatic sections from the vehicle-treated animals
had the least insulin staining (Fig. 2B). The color intensity was
calculated for individual -cells within the islets and the means
are provided in Fig. 2D. Analysis of proinsulin staining from
immunoﬂuorescence images revealed the highest levels of proin-
sulin in the liraglutide-treated rats (pixel intensity units 44.3 ± 3.7)
compared to 37.3 ± 2.1 for the diabetic vehicle-treated rats, and
29.2 ± 3.0 in the lean controls (p < 0.005).
Consistent with the immunohistochemistry data showing
greater insulin staining, the density of insulin granules in the -cells
of islets from the liraglutide-treated animals increased as compared
to the controls. Insulin granules were identiﬁed by their hallmark
halo appearance in electron micrographs, illustrated by arrows in
Fig. 3A. The -cells from the liraglutide-treated animals possessed
a higher density of insulin granules per -cell area than the vehicle-
treated animals (Fig. 3B).
Insulin secretion was  measured from isolated islets from the
3 groups in conditions of 1 mM,  3 mM and 20 mM glucose. Islets
from the lean animals showed a typical response with little stimu-
lation at 3 mM glucose, but a signiﬁcant increase in insulin release
at 20 mM (Fig. 3C, p < 0.01). There was no signiﬁcant increase in the
amount of insulin released from the islets of vehicle-injected rats in
response to 20 mM glucose. The liraglutide-treated rats had islets
with a stimulation index that was not statistically different from
T. Schwasinger-Schmidt et al. / Pharmacological Research 76 (2013) 58– 66 61
Fig. 1. Metabolic characteristics. (A) Body weights for the vehicle-treated animals were higher than the lean non-diabetic controls or the liraglutide-treated diabetic rats
(p  < 0.05). (B) The non-fasting blood glucose levels for the 2 diabetic groups were signiﬁcantly higher than the lean controls at each time point measured (p < 0.001). The
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he lean control rats, but was higher than the 3 mM exposure in the
slets from liraglutide-treated rats (p < 0.001).
.3. Islet morphology
Morphological differences between groups clarify the cellular
hanges that occur with diabetes. The lean controls had healthy
ppearing -cells with normal islet morphology consisting of cen-
rally located -cells and - and -cells on the periphery (Fig. 4A).
his cellular architecture was consistent with 88% of all islets from
he lean controls demonstrating a -cell core pattern (n = 41 islets
rom 3 rats). Only 6% of the islets from the diabetic vehicle-treated
ats were organized with the -cell core (n = 113 islets from 4 rats).
iraglutide did not improve the cellular architecture, because only
ig. 2. Cellular insulin levels. (A) Immunohistochemistry of pancreatic sections stained fo
at.  (B) Islets from the vehicle-treated animals possessed weak insulin staining. (C) The is
han  the vehicle group. (D) The graph summarizes these ﬁndings, showing the insulin inte
reated animals, but statistically less than the non-diabetic lean controls. The graph summ
he  lean controls and the vehicle-treated group (p < 0.001). #Difference between the vehi-treated group (p < 0.02). (C) Glucose tolerance tests illustrated the rapid increase
reached its maximum detectible level within 15 min  of the injection. None of the
1% of the islets from the treated group had -cell cores (n = 71 islets
from 4 rats).
In addition to the location of speciﬁc endocrine cell types within
the islets, the overall shape of the islets was altered with diabetes.
In the diabetic animals, the islets often had a disrupted appearance
with large areas in the islet core void of endocrine cells or areas of
scattered endocrine cells amongst exocrine tissue (Fig. 4B and C).
We identiﬁed 3 major islet morphology categories: (1) intact, (2)
disrupted and (3) scattered cells. In the lean animals, the major-
ity of the islets were intact with approximately 15% classiﬁed as
disrupted islets or scattered endocrine cells (Table 1). A major-
ity of the islets in the vehicle-treated rats were disrupted, with
entire sections of islets missing endocrine cells as shown in Fig. 4B.
The liraglutide-treated animals had a majority of islets classiﬁed as
r insulin shows the most intense insulin staining in an islet from a lean non-diabetic
lets from the liraglutide-treated animals illustrated more intense immunostaining
nsity/cell with the liraglutide group possessing more insulin/cell than the vehicle-
arizes analysis of an average of 22 islets/group from 9 sections. *Difference between
cle- and liraglutide-treated groups (p < 0.05). Scale bar = 100 m for all images.
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Fig. 3. Insulin granules. (A) Micrograph of sample islet cells from a vehicle-treated animal. White arrows indicate insulin granules (magniﬁcation = 1500×). (B) Analysis of
insulin  granule density demonstrated that the 2 diabetic groups had a lower granule density than the lean control animals. An average of 36 islets/group were analyzed from
3  rats/group (*p < 0.001 and #p < 0.05). (C) The glucose-stimulated insulin release (stimula
2  independent trials (2–3 replicates). Islets from the lean control animals and the liragluti
glucose  compared to 3 mM glucose (*p < 0.01).
Fig. 4. Morphology of islets. (A) Antibody-labeled islets from non-diabetic lean
control animals illustrated a normal morphology. (B) The islets from the vehicle-
treated diabetic rats had large areas of missing cells, indicating disrupted islets. (C)
The pancreatic sections from liraglutide-treated animals appeared similar to the
vehicle-treated group. Counter staining with DC34 for blood vessels (shown sur-
rounding the islet) and insulin and proinsulin (staining the islets) from lean controls
(
w
b
e
d
t
g
n
e
b
a
t
p
i
T
I
T
f
w
T
s
aD), vehicle-treated (E) and liraglutide-treat (F) animals all had similar vascularity
ith less proinsuilin in the 2 diabetic groups (vehicle and liraglutide-treated). Scale
ar = 100 m for all images.
ither disrupted or scattered cells (Table 1). There was  no statistical
ifference between the 2 diabetic groups (vehicle or liraglutide-
reated) for any of the classiﬁcations compared. However, both
roups were statistically different from the islets obtained from the
on-diabetic lean animals, except for the classiﬁcation of scattered
ndocrine cells.
The disrupted appearance of many of the islets from the 2 dia-
etic groups led to questions about the vascularity of the islets
ssociated with diabetes and liraglutide treatment. Pancreatic sec-
ions were stained with CD34 to identify vessels surrounding and
enetrating the islets. Fig. 4D shows the vessel staining around an
slet from a lean control rat. The green cells within the islets are
able 1
slet morphological categories.
Intact Disrupted Scattered
Lean 84.1 ± 5.3* 7.9 ± 4.1* 7.7 ± 3.3
Diabetic vehicle 21.8 ± 12.0 67.33 ± 15.3 11.2 ± 5.0
Diabetic liraglutide 12.4 ± 5.5 47.0 ± 7.1 40.4 ± 8.2*
he percentage of intact islets was greatest in the lean, non-diabetic group. Islets
rom the two diabetic groups showed substantial numbers of disrupted islets, in
hich the outer capsule of the islet was damaged and lacked a smooth border.
he  percentage of islets with disrupted outer rims was  the same as small clusters of
cattered endocrine cells in the pancreata from liraglutide-treated animals. n = slides
nalyzed (lean = 8, vehicle = 8, liragluide-treated = 7).
* p < 0.05.tion index) was measured from isolated islets. The graph summarizes the mean of
de-treated group had a signiﬁcant increase in insulin release in response to 20 mM
positive for insulin (-cells) with proinsulin additionally stained in
red/orange. As has been shown in the past, blood vessels appear
to align with the insulin-containing portion of each -cell and
opposite the proinsulin location in the healthy rats [17]. The
vehicle-treated rats had evidence of abundant blood vessels that
penetrated throughout the islets with a more scattered distribu-
tion of proinsulin within each cell (Fig. 4E). Liraglutide did not
change the appearance or density of blood vessels within the islets
(Fig. 4F). More proinsulin was  located in -cells near blood ves-
sels in the liraglutide-treated animals than in the vehicle treated
diabetics.
3.4. ˛-Cells and glucagon content
There was  no signiﬁcant difference in the percentage of -
cells present in individual islets between groups (68.1 ± 2.5% in
lean controls, 72.8 ± 2.0% in vehicle-treated, and 67.4 ± 3.2% in
liraglutide-treated rats). However, when the total area per micro-
scopic ﬁeld stained for glucagon was calculated, there was far less
glucagon in the liraglutide-treated animals than in either of the
other two groups (Fig. 5A). A difference in glucagon staining per
islet could be due to changes in cell size (hypertrophy or atro-
phy) or in cell number. To clarify, individual - and -cell numbers
were counted using 40× images and the liraglutide group again
had signiﬁcantly fewer -cells/ﬁeld than the other two groups
(Fig. 5B). There was  no difference in the number of -cells/ﬁeld
(lean = 17.4 ± 5.6; vehicle = 14.2 ± 2.3; liraglutide = 12.3 ± 1.6). The
loss of -cells resulted in an increase in the -cell/-cell ratio
(Fig. 5C). In addition, the intensity of the glucagon staining within
each -cell was  signiﬁcantly lower in the two  diabetic groups com-
pared to the lean controls (Fig. 5D). In -cells, there was signiﬁcantly
less somatostatin staining in the liraglutide treated cells compared
to the other two groups (Fig. 5E).
3.5. Cell proliferation
To begin to identify the mechanisms responsible for the changes
in - to -cell ratios, we identiﬁed proliferating cells using Ki67,
a well-characterized nuclear protein essential for proliferation. In
the lean, non-diabetic animals positive Ki67 staining was  present
in 14% of all of the -cells (Table 2). In contrast, only half that many
-cells were proliferating in the vehicle-injected diabetic rats, and
there were no proliferating -cells in the liraglutide-treated ani-
mals. In contrast, the percentage of -cells actively proliferating
was higher in both diabetic groups compared to the non-diabetic
group. The liraglutide group had lower -cell proliferation rates
than the vehicle-treated rats (Table 2).
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Fig. 5. -Cell survival and glucagon content. (A) Analysis of triple stained images conﬁrmed that there was  less glucagon staining when measured as total pixels. An average
of  7 sections/group were analyzed with 16.2 islets/section (*p  < 0.001). (B) There were fewer glucagon-positive -cells per ﬁeld. An average of 44 ﬁelds from 9 sections/group
were  analyzed (*p < 0.01). (C) The -cell to -cell ratio was highest in the liraglutide-treated animals. An average of 7 sections/group were analyzed with 16.2 islets/section
(*p  < 0.05). (D) The intensity of the glucagon staining within each -cell was decreased in the liraglutide-treated animals. An average of 5 sections/group were analyzed with
35  cells/islet (*p < 0.01). (E) The intensity of the somatostatin immunostaining within eac
of  8 sections/group were analyzed from 12 cells/islet (*p < 0.001).
Table 2
- and -cell proliferation rates.
-Cells -Cells Other
Lean 14.3 ± 1.1 28.6 ± 5.9 64.3 ± 8.5
Diabetic vehicle 6.7 ± 0.9 80.0 ± 6.5* 82.2 ± 1.0*
Diabetic liraglutide 0.0 ± 0.0 56.6 ± 2.5 56.8 ± 4.7
Positive Ki-67 staining indicated proliferating cells. In the lean, non-diabetic animals
there was a low level of proliferating - or -cells compared to other cells in the islet.
However, in the diabetic, vehicle-administered animals the -cells had a high level
of  proliferation. Administration of liraglutide signiﬁcantly reduced the proliferating
-cells with no proliferation found in -cells. n = 17 islets from lean rats, 15 diabetic
vehicle rats, and 17 diabetic liraglutide rats.
* p < 0.05 for comparison within -cells and other cell types.h -cell was signiﬁcantly decreased in the liraglutide-treated animals. An average
3.6. Mitochondrial ultrastructure
Given the loss of -cells in the islets of the liraglutide-treated
rats, we  investigated the ultrastructure of these cells. The quality
of the mitochondria, based on EM micrographs, was scored using
the Mitochondrial Quality Index [14]. The sample image of an -
cell from a lean control rat illustrates healthy mitochondria given
a score of 1 (Fig. 6A). -Cells from vehicle- and liraglutide-treated
animals illustrate mitochondria with scores of 2, 3 and 4 (Fig. 6B
and C). In -cells, only the cells from lean control animals had a
predominance of healthy mitochondria with no signs of completely
disrupted mitochondria (Fig. 6D). Cells from the vehicle and liraglu-
tide treated groups had nearly equal numbers of mitochondria in all
4 quality categories. Likewise, in -cells from the lean control ani-
mals, the majority of mitochondria were completely intact (Fig. 6E).
In contrast, -cells from the liraglutide-treated animals had a much
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Fig. 6. Mitochondria quality index score. (A) Electron micrographs illustrated the intact mitochondria in an -cell from a lean control animals (black arrows). (B and C)
Vehicle and liraglutide-treated animals had -cells with disrupted mitochondria with MQI  scores of 2–4 (white arrows). (D) There was  no difference in the MQI  score
for  -cells between the vehicle and liraglutide-treated groups. Mitochondrial integrity from the lean controls was signiﬁcantly higher compared to the other 2 groups
(p  < 0.001). (E) -Cell mitochondrial integrity was also greatest in the lean control animals (*p < 0.001). There were signiﬁcantly more disrupted mitochondria (score of 4) in
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igher percentage of the mitochondria that were completely dis-
upted (score of 4) compared to the vehicle-treated rats (Fig. 6E).
. Discussion
The results of this study indicate that long-term liraglutide treat-
ent reduced weight gain and lowered blood glucose in severely
iabetic ZDF rats. However, an excessive loss of -cells, without a
oss in -cell number, was observed with markedly abnormal islet
orphology. In spite of the bihormonal hypothesis ﬁrst proposed
y Unger and Orci in 1975 [18], little has been done to explore
he role of the -cell and glucagon secretion with GLP-1 analogs. It
as been known for over 15 years that GLP-1 suppresses glucagon
elease [19], and this suppression is not dependent on the increased
nsulin secretion stimulated by the compound, as it occurs even
n cultured -cell lines [9]. Furthermore, the increase in islet size
eported in some studies with GLP-1 treatment was due to the stim-
lation of -cell proliferation [20], with no observable changes in
ther cell types. Liraglutide was shown to increase -cell mass by
ncreasing the cellular kinetics and suppressing ER stress in db/db
ice after only 2 weeks of treatment. Our study, conducted for
 weeks on severely diabetic rats, showed islets with abnormal
orphology in both the vehicle and liraglutide-treated groups with
xcessive loss of -cells in the treated animals.
In ZDF rats, liraglutide has been reported to initially reduce body
eight, but the animals gained the weight back, so that within 6ages analyzed were collected at 1500× magniﬁcation.
weeks of treatment they were statistically heavier than the vehicle-
treated rats [6]. In our study, 9 weeks of treatment resulted in
a signiﬁcant decline in weight compared to animals exposed to
vehicle alone, resulting in body weights that were not statisti-
cally different from the lean controls. Similar consistent losses in
body weight have been identiﬁed in db/db mice [21]. In agreement
with our ﬁndings, previous studies using ZDF rats and liraglutide
monotherapy noted a decline in blood glucose levels with liraglu-
tide, but this reduction did not bring the glucose levels down to
nondiabetic values [6,22].
The endocrine function of the islet is a delicate balance of both
paracrine, endocrine, neural and possibly vascular communication.
Thus, changes in the cellular equilibrium must be investigated since
they may  ultimately affect the clinical response to chronic expo-
sure of high levels of GLP-1. In another study employing long-term
liraglutide treatment, there was  no increase in the -cell mass or Ki-
67 staining in male ZDF rats [22]. In Sturis et al., proliferating -cells
numbers actually dropped with 2 weeks of liraglutide administra-
tion, but then returned to vehicle levels by week 6 [6]. We  show
a decline in - and -cell proliferation along with a decline in
all cell proliferation in the islets with liraglutide treatment com-
pared to the vehicle group, in sharp contrast to the current dogma
concerning -cell proliferation and GLP-1 analogs. It is important
to note that the greatest reported increase in -cell proliferation
with liraglutide has been in primary monolayer cultures from new-
born rats [20], and not in vivo studies. Even when there was a
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eported increase in proliferating -cells in intact islets in response
o liraglutide, those proliferating cells were still extremely rare
vents in both human and rat islets [23,24]. Thus, the exact level
f -cell proliferation in humans in response to liraglutide is still
nclear.
The impact of GLP-1 and its analogs on -cells has been uncer-
ain. In isolated rat and human islets, GLP-1 exposure signiﬁcantly
ecreased the content and release of glucagon from -cells [8,25].
hile in the perfused rat pancreas, GLP-1 had no effect on glucagon
elease [26]. In humans, liraglutide caused signiﬁcantly lower
lucagon levels when fasting and following meals [27] especially
rotein-rich meals [28]. In one of the most interesting experiments,
umans were subjected to a step-wise hypoglycemic clamp and
lasma glucagon levels sampled. At both 4 and 5 mM glucose, the
ubjects given liraglutide showed signiﬁcantly less glucagon secre-
ion than the placebo group [29,30]. At even lower glucose levels
down to 2.7 mM)  there was either no effect of liraglutide, or the
iraglutide group actually secreted more glucagon than the placebo
roup [30]. However, it is important to note that those tests utilized
cute (30 min) exposures to GLP-1 or GLP-1 analogs (exendin), and
ay  not be relevant to potential changes that could occur with
ong-term exposure. A human study of type 2 diabetic patients
dministered liraglutide for 12 weeks found a reduction in fas-
ing glucagon with all 5 liraglutide doses tested, although statistical
igniﬁcance was not reached [4].
Importantly, a recent article describing the effects of long-term
xposure to GLP determined that there was greater -cell mass
n humans treated with incretins for more than 1 year compared
o diabetics on other drugs [31]. The subjects on the incretins had
xpanded numbers of glucagon-positive cells lining the pancreatic
ucts associated with increased, but still rare, Ki-67 staining. The
esults of this study are at odds with our ﬁndings. However, it is
mportant to note that the human organ donors studied in Butler
t al. were taking sitagliptin, a DPP-4 inhibitor (n = 6) and one was
n exenatide. The differences between our ﬁndings and the human
tudy may  certainly be due to the aspects unique to ZDF rats, or
ay  be drug speciﬁc as we only tested the effects of liraglutide.
urther studies are vital to determine the long-term effects of drugs
ithin the incretin classiﬁcation on -cell health and pancreatic
unction.
Other human studies on the long-term effects of GLP-1 analogs
ave begun to raise concerns about the safety of this class of drugs
32,33]. While the majority of the studies have examined possi-
le links between the use of another GLP-1 agonist, exendin, likely
ecause it has been on the market longer, new reports includ-
ng case studies, indicate a possible link with liraglutide as well
34–36]. In the past 2 years, the FDA has issued warnings con-
erning the use of liraglutide with possible risks of thyroid cancer,
ancreatitis, and lost renal function [37]. Although studying these
omplications was not the focus of this study, no obvious signs of
ancreatitis were noted in the liraglutide-treated animals.
. Conclusions
This study, along with previous publications, showed that
iraglutide had positive metabolic effects on the ZDF rat model,
ncluding reduced weight gain and decreased non-fasting blood
lucose levels. However, this study also demonstrates abnormal
slet morphology associated with severe diabetes that was not
eversed by liraglutide and, in the case of -cell health, was actually
nferior in the treated group. Any hope of stabilizing or enhanc-
ng islet cell mass or function must be accompanied by studies
hat carefully assess islet anatomy and physiology. The relevance
f these ﬁndings to humans needs to be investigated, along with
nvestigations of the mechanism of -cell loss.
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